BPC-157 (body protection compound, 15-amino-acid peptide derived from a gastric protein) sits in the most-asked-about peptide tier in nootropic and recovery communities. The mechanistic case is interesting; the evidence case is thin. This guide covers what's known about dosing and where the dose recommendations actually come from.
Where the dose recommendations come from
The honest framing first. Essentially all BPC-157 dose recommendations are extrapolated from rodent studies, cell culture experiments, and a handful of small case reports. There is no completed peer-reviewed human RCT with a published dose-response curve. The Sikiric review covers the preclinical breadth across gut, tendon, vascular, and neurological models Sikiric P et al 2018 .
The standard human-equivalent dose calculation goes: rodent studies use 10 to 20 mcg/kg/day. For a 70 kg adult, that translates to 700 to 1,400 mcg/day. Most consumer protocols cluster well below this range (250 to 500 mcg/day) for safety margin. Whether the lower doses produce the effects seen in animal studies is unanswered.
For users running BPC-157, the dose is an empirical bet on rodent-to-human extrapolation rather than a settled clinical recommendation. The compound's safety record at supplemental doses is reasonable in case-report literature; the efficacy claim is preclinical.
Subcutaneous dosing protocol
The most common route for non-gut targets.
- Daily dose: 250 to 500 mcg/day, single morning injection
- Site: abdominal subcutaneous fat (most common) or near target tissue (e.g. peri-patellar for knee, near supraspinatus for shoulder)
- Equipment: 27-31 gauge insulin syringe, ~5/16 inch needle
- Reconstitution: bacteriostatic water at manufacturer ratio (typically 5 mg vial reconstituted to 5 mL = 1 mg/mL = 100 mcg per 0.1 mL on a U-100 syringe)
- Cycle: 4 to 6 weeks for acute injury; longer for chronic systemic use under careful monitoring
The localized injection rationale is that BPC-157 has tissue-affinity properties in animal studies; injection near the target may improve local delivery. The trial evidence for this versus generic abdominal SC dosing is absent; both protocols are used.
For tendon and ligament injuries, the most-reported protocols are 4-6 weeks of daily injection at 250-500 mcg, paired with conservative loading and standard physical therapy. Subjective recovery acceleration is the typical user-reported outcome; controlled comparison against placebo or PT-only is not available.
Oral dosing protocol
Oral BPC-157 is the most-defensible route for gut-localized targets and the least-defensible for systemic ones.
The mechanistic case for oral delivery in gut indications: the peptide acts locally on intestinal epithelium, gut-associated lymphoid tissue, and the gut microbiome before degradation. Sikiric's preclinical work shows reproducible benefit in IBD models, NSAID-induced gut damage, and gastric ulcer healing Sikiric P et al 2018 .
For systemic targets (tendon, joint, neurological), oral bioavailability is the open question. The 15-amino-acid peptide is partially degraded by gut proteases; what fraction of intact peptide reaches systemic circulation is uncharacterized in humans. Subcutaneous is the preferred route for non-gut targets in most protocols.
- Daily dose: 500 mcg twice daily for gut-localized use
- Form: capsule or sublingual tablet; powder reconstituted into water also used
- Timing: with or before meals for gut-localized targets
- Cycle: 4-8 weeks for acute gut conditions; longer continuous use under specialist guidance for chronic conditions
The oral dose is double the subcutaneous dose to compensate for partial gut degradation. Whether this fully compensates is unknown.
Cycling protocols
The conventional pattern is 4-6 weeks on, 4-8 weeks off. No trial evidence dictates this pattern; it reflects nootropic-community caution about chronic peptide exposure rather than biological necessity.
The case for cycling: theoretical concerns about chronic angiogenesis (BPC-157 promotes blood-vessel growth) and unknown long-horizon effects. The reverse case: acute injuries often resolve in 2-4 weeks; chronic gut conditions may benefit from longer continuous protocols.
For users running BPC-157:
- Acute injury: 2-4 weeks until subjective resolution, then stop
- Chronic conditions (IBD, recurrent tendinopathy): 6-8 weeks on, 4-6 weeks off, multiple cycles per year
- Performance / general recovery use: 4-6 weeks 2-3x per year, paired with intensive training blocks
Reconstitution math
For 5 mg lyophilized vials (the most common consumer format):
- Add 5 mL bacteriostatic water for 1 mg/mL concentration
- 0.05 mL on a U-100 insulin syringe = 5 units = 50 mcg
- 0.10 mL = 10 units = 100 mcg
- 0.25 mL = 25 units = 250 mcg (typical low daily dose)
- 0.50 mL = 50 units = 500 mcg (typical high daily dose)
Reconstituted peptide is stable refrigerated for 2 to 4 weeks per most manufacturers. Discard if cloudy or visible particles develop.
Safety: what's known and what isn't
The case-report safety profile is reasonable. Most users report no significant adverse effects at typical doses. Reported events include transient injection-site reactions, occasional mild GI symptoms with oral use, and rare reports of headache or fatigue.
What's not known is long-term safety in healthy adults. The compound's angiogenic properties produce theoretical concerns about cancer (in active malignancy) and vascular pathology (in patients with existing endothelial dysfunction). These concerns are theoretical and not supported by case-report data, but human trial-grade safety data are absent.
Active cancer is a relative contraindication. Pregnancy and lactation lack data. Users with active vascular disease (post-recent-MI, active CVD treatment) should avoid pending clearer data.
Cross-links and further reading
- BPC-157 compound profile for the mechanism, regulatory status, and side-effect detail
- Dosage guide template for the protocol shape
- Recovery protocols overview for the broader recovery toolkit
For users considering BPC-157: the dose protocols above are the most-defensible empirical estimates given absent human RCT data. Treat the compound as an experimental recovery intervention with mechanistic interest and weak human evidence, not a settled clinical recommendation.
